BCAB Stock Analysis: Buy, Sell, or Hold?

BCAB - BioAtla, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
$3.80
-0.02 (-0.52%) ▼
5d: -17.03%
30d: +4.11%
90d: -14.8%
HOLD
MODERATE Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 06, 2026 23d

Get Alerted When BCAB Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
📊 HOLD: BCAB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
See Forward Earnings Fair Value & Price Prediction →

In-depth Analysis How we analyze

Valuation Analysis: BCAB is currently trading at $3.80, which is considered fair relative to its 30-day fair value range of $3.44 to $4.02.

Technical Outlook: Technically, BCAB is in a strong uptrend. Immediate support is located at $3.48, while resistance sits at $4.73.

Market Sentiment: BCAB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.00 (+161.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position FAIR
Historical Trading Range $3.44 - $4.02
Company Quality Score 55/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 50.0%

All Signals

  • NEUTRAL: Price in fair range
  • BEARISH: Weak technical setup (25/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 161.8% below Wall St target ($10.00)
  • CAUTION: 5-day price weakness (-17.0%) - monitor closely

Trading Range Analysis

30-Day Trading Range $3.44 - $4.02
Current vs Trading Range FAIR

Support & Resistance Levels

Support Level $3.48
Resistance Level $4.73
Current Trend Strong Uptrend
Technical data as of Jul 10, 2026

Fundamental Context

Forward P/E (Next Year Est.) -2.86
Wall Street Target $10.00 (+161.8%)
Revenue Growth (YoY) 31.6%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: July 13, 2026 10:24 AM ET
Data refreshes hourly during market hours. Next update: 11:24 AM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for BCAB.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
ALNY
Alnylam Pharmaceuticals …
STRONG BUY
30 analysts
$441 62 BUY
RARE
Ultragenyx
STRONG BUY
20 analysts
$52 61 BUY
JAZZ
Jazz Pharmaceuticals PLC
STRONG BUY
18 analysts
$258 65 BUY
BBIO
BridgeBio Pharma Inc
STRONG BUY
19 analysts
$102 64 BUY
NRIX
Nurix Therapeutics Inc
STRONG BUY
18 analysts
$32 63 BUY

More Analysis for BCAB

BCAB Technical Chart BCAB Price Prediction BCAB Earnings Date BCAB Investment Advisor BCAB Fair Price Analyzer BCAB Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals